Edition:
United States

MediciNova Inc (MNOV.OQ)

MNOV.OQ on NASDAQ Stock Exchange Global Market

5.46USD
26 Jun 2017
Change (% chg)

-- (--)
Prev Close
$5.46
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
19,978
52-wk High
$8.00
52-wk Low
$4.87

MNOV.OQ

Chart for MNOV.OQ

About

Medicinova, Inc. is a biopharmaceutical company. The Company focuses on acquiring and developing small molecule therapeutics for the treatment of diseases with unmet medical needs and a commercial focus on the United States market. Its pipeline includes MN-166 (ibudilast), MN-001 (tipelukast), MN-221 (bedoradrine) and MN-029... (more)

Overall

Beta: 0.22
Market Cap(Mil.): ¥21,290.11
Shares Outstanding(Mil.): 34.54
Dividend: --
Yield (%): --

Financials

  MNOV.OQ Industry Sector
P/E (TTM): -- 242.00 19.11
EPS (TTM): -34.47 -- --
ROI: -26.51 -8.00 -5.00
ROE: -29.21 -10.45 -4.24

BRIEF- MediciNova completes off-floor distribution

* Says it completes the off-floor distribution of shares on June 13

Jun 12 2017

BRIEF- MediciNova to offer off-floor distribution of shares

* Says it will offer an off-floor distribution of 800,000 shares of its stock at the price of 602 yen per share, on the Tokyo Stock Exchange on June 13

Jun 12 2017

BRIEF-MediciNova to offer off-floor distribution of shares

* Says it will offer an off-floor distribution of 800,000 shares on Tokyo Stock Exchange, from June 13 to June 15

Jun 05 2017

BRIEF-Medicinova announces positive findings from completed trial of MN-166 research

* Medicinova announces positive findings from completed trial of MN-166 (ibudilast) in methamphetamine dependence presented at the 50th winter conference on brain research Source text for Eikon: Further company coverage:

Feb 06 2017

BRIEF-Medicinova announces positive findings on MN-166 (ibudilast) in alcohol dependence

* Medicinova announces publication of positive findings on MN-166 (ibudilast) in alcohol dependence

Jan 23 2017

More From Around the Web

Earnings vs. Estimates